COSMO Pharmaceuticals SA (LSE:0RGI) — Market Cap & Net Worth
Market Cap & Net Worth: COSMO Pharmaceuticals SA (0RGI)
COSMO Pharmaceuticals SA (LSE:0RGI) has a market capitalization of $1.64 Billion (£1.22 Billion) as of May 3, 2026. Listed on the LSE stock exchange, this UK-based company holds position #7004 globally and #17 in its home market, demonstrating a -13.43% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying COSMO Pharmaceuticals SA's stock price £81.43 by its total outstanding shares 15002100 (15.00 Million). Analyse 0RGI cash generation efficiency to see how efficiently the company converts income to cash.
COSMO Pharmaceuticals SA Market Cap History: 2015 to 2026
COSMO Pharmaceuticals SA's market capitalization history from 2015 to 2026. Data shows change from $3.25 Billion to $1.64 Billion (-6.38% CAGR).
COSMO Pharmaceuticals SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how COSMO Pharmaceuticals SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.81x
COSMO Pharmaceuticals SA's market cap is 4.81 times its annual revenue
Latest Price to Earnings (P/E) Ratio
9.63x
COSMO Pharmaceuticals SA's market cap is 9.63 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $3.25 Billion | $60.61 Million | $248.19 Million | 53.63x | 13.10x |
| 2016 | $3.28 Billion | $67.66 Million | $19.34 Million | 48.52x | 169.77x |
| 2017 | $2.91 Billion | $67.24 Million | -$32.45 Million | 43.21x | N/A |
| 2018 | $1.77 Billion | $65.62 Million | -$18.06 Million | 27.00x | N/A |
| 2019 | $1.54 Billion | $62.49 Million | -$24.49 Million | 24.71x | N/A |
| 2020 | $1.71 Billion | $60.95 Million | -$7.90 Million | 27.98x | N/A |
| 2021 | $1.32 Billion | $65.07 Million | $21.67 Million | 20.25x | 60.80x |
| 2022 | $1.24 Billion | $102.09 Million | $17.23 Million | 12.17x | 72.10x |
| 2023 | $1.03 Billion | $92.78 Million | -$4.93 Million | 11.14x | N/A |
| 2024 | $1.28 Billion | $266.79 Million | $133.24 Million | 4.81x | 9.63x |
Competitor Companies of 0RGI by Market Capitalization
Companies near COSMO Pharmaceuticals SA in the global market cap rankings as of May 3, 2026.
Key companies related to COSMO Pharmaceuticals SA by market ranking:
- Arcelik AS (IS:ARCLK): Ranked #6995 globally with a market cap of $1.64 Billion USD ( TL73.42 Billion TRY).
- Friedrich Vorwerk Group SE (F:VH2): Ranked #6996 globally with a market cap of $1.64 Billion USD ( €1.41 Billion EUR).
- Shanxi Huaxiang Group Co Ltd (SHG:603112): Ranked #7005 globally with a market cap of $1.64 Billion USD ( CN¥11.21 Billion CNY).
- Sinostone Guangdong Co Ltd (SHE:001212): Ranked #7006 globally with a market cap of $1.64 Billion USD ( CN¥11.21 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #6995 | Arcelik AS | IS:ARCLK | $1.64 Billion | TL111.90 |
| #6996 | Friedrich Vorwerk Group SE | F:VH2 | $1.64 Billion | €72.75 |
| #7005 | Shanxi Huaxiang Group Co Ltd | SHG:603112 | $1.64 Billion | CN¥20.75 |
| #7006 | Sinostone Guangdong Co Ltd | SHE:001212 | $1.64 Billion | CN¥55.77 |
COSMO Pharmaceuticals SA Historical Marketcap From 2015 to 2026
Between 2015 and today, COSMO Pharmaceuticals SA's market cap moved from $3.25 Billion to $ 1.64 Billion, with a yearly change of -6.38%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | £1.64 Billion | -22.60% |
| 2025 | £2.12 Billion | +65.25% |
| 2024 | £1.28 Billion | +24.13% |
| 2023 | £1.03 Billion | -16.81% |
| 2022 | £1.24 Billion | -5.74% |
| 2021 | £1.32 Billion | -22.73% |
| 2020 | £1.71 Billion | +10.43% |
| 2019 | £1.54 Billion | -12.85% |
| 2018 | £1.77 Billion | -39.01% |
| 2017 | £2.91 Billion | -11.51% |
| 2016 | £3.28 Billion | +1.01% |
| 2015 | £3.25 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of COSMO Pharmaceuticals SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.64 Billion USD |
| MoneyControl | $1.64 Billion USD |
| MarketWatch | $1.64 Billion USD |
| marketcap.company | $1.64 Billion USD |
| Reuters | $1.64 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About COSMO Pharmaceuticals SA
Cosmo Pharmaceuticals N.V. focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesa… Read more